How the Medicare GLP-1 Bridge Actually Works: Prior Authorization, Claims, and the $50 Copay Explained

On July 1, 2026, Medicare did something it had never done before: it started paying for GLP-1 medications used purely for weight loss. The vehicle is the Medicare GLP-1 Bridge, a temporary CMS demonstration that lets eligible Part D beneficiaries fill Wegovy, the Zepbound KwikPen, or Foundayo for a flat $50 per month.

KFF estimates that nearly four million Medicare beneficiaries met the eligibility criteria based on 2023 data — so this is not a niche program. But the Bridge is also one of the more unusual coverage mechanisms Medicare has ever run. It doesn’t flow through your Part D plan the way a normal prescription does. It requires a prior authorization with a sworn attestation under penalty of perjury. And the $50 you pay, oddly, doesn’t count toward your annual out-of-pocket cap.

This is our complete, sourced walkthrough of how the Bridge works — eligibility, covered drugs, the copay mechanics, the prior authorization process, and the end-to-end claims flow — written for patients and the clinicians and pharmacists who serve them. For the broader July news, see our July 2026 GLP-1 updates.

This is educational information, not medical or legal advice. Program rules can change. Always confirm your specific situation with your prescriber, pharmacy, plan, or 1-800-MEDICARE.

What the Bridge Is (and Isn’t)

The Medicare GLP-1 Bridge is a short-term demonstration run by CMS that provides eligible Medicare Part D beneficiaries access to certain GLP-1 drugs between July 1, 2026 and December 31, 2027. It is explicitly temporary.

Two things make it structurally different from ordinary Part D coverage:

1. The drugs are furnished outside the normal Part D benefit payment flow. Instead of your plan adjudicating and paying the claim, CMS uses a single central processor to handle prior authorization, claims adjudication, and payment to pharmacies.
2. Your Part D plan carries no risk and doesn’t have to opt in. Whether your plan wanted to cover weight-loss GLP-1s or not is irrelevant — if you’re eligible, you can access the drugs starting July 1, 2026.

CMS has framed the Bridge partly as a data-collection exercise: it lets the agency gather GLP-1 utilization data to share with Part D plan sponsors ahead of the potential future implementation of the BALANCE Model in Part D (more on that below). In other words, the Bridge is a stopgap that keeps drugs flowing to patients while the longer-term policy is still being built.

Who Is Eligible

Eligibility has three layers — plan enrollment, clinical criteria, and a set of exclusions that trip up more people than you’d expect.

1. Plan Enrollment

You must be enrolled in a Medicare drug plan — either:

• A standalone Prescription Drug Plan (PDP), or
• A Medicare Advantage coordinated care plan that includes drug coverage (MA-PD) — HMO, HMO-POS, and Local/Regional PPO plans.

There is no separate enrollment or opt-in for the Bridge itself. If you’re eligible, the pathway is available to you automatically. You can check eligibility at Medicare.gov/glp1bridge or by calling 1-800-MEDICARE (1-800-633-4227).

2. Clinical Criteria

You must meet one of these three tiers at the time GLP-1 therapy was initiated, and be at least 18 years old:

• BMI ≥ 35, or
• BMI ≥ 30 with heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension (systolic > 140 or diastolic > 90 mm Hg despite two or more medications), or chronic kidney disease (stage 3a or above), or
• BMI ≥ 27 with pre-diabetes (per ADA guidelines), a previous heart attack (myocardial infarction), a previous stroke, or symptomatic peripheral artery disease.

The “at initiation” detail matters. If you started a GLP-1 in, say, September 2024 at a BMI of 37 and you’ve since dropped to a BMI of 34, you still qualify — the prescriber attests that you met the BMI ≥ 35 threshold when therapy began, not today. The program is designed to keep working patients on treatment, not to punish them for losing weight.

3. The Exclusions (Read These Carefully)

This is where many otherwise-eligible people fall out. You are not eligible for the Bridge if:

• You already filled a GLP-1 prescription under your Part D plan in 2026. The Bridge is meant to be a bridge — not a supplement to coverage you already have.
• You have a diagnosis that is already a medically-accepted Part D indication for a GLP-1. CMS specifically calls out type 2 diabetes, moderate-to-severe obstructive sleep apnea (OSA), and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH). If you have one of these, your GLP-1 can already be covered under ordinary Part D, so you go through that route instead of the Bridge.

In practice, the Bridge is aimed squarely at people whose only reason for a GLP-1 is weight reduction — the exact population Medicare historically refused to cover.

What’s Covered — and What Isn’t

An “eligible GLP-1 drug” under the Bridge is any of the following when used to reduce excess body weight and maintain weight reduction:

Drug	Formulations covered
Foundayo (orforglipron)	All formulations (oral tablet)
Wegovy (semaglutide)	All formulations — both injection and oral tablets
Zepbound (tirzepatide)	KwikPen only

Two important carve-outs on the Zepbound side: the single-dose Zepbound pen and Zepbound vials are NOT covered under the Bridge. Only the multi-dose KwikPen formulation qualifies. Coverage is limited to a single monthly supply — a 28- or 30-day fill — at the $50 copay; larger quantities are not covered per fill.

The $50 Copay, Explained

The copay is a flat $50 per 30-day supply, and it’s the beneficiary’s total out-of-pocket cost for the drug. But three mechanics surprise people:

• The Part D deductible does not apply. You don’t have to “meet your deductible” first — it’s $50 from the first fill.
• The $50 does not count toward your TrOOP. TrOOP (“true out-of-pocket”) is the running total that pushes you toward Medicare’s catastrophic-coverage threshold and the annual out-of-pocket cap. Because Bridge drugs are furnished outside the Part D benefit, none of what you pay counts toward that cap. If you have other expensive Part D drugs, this is a real (if subtle) downside.
• There is no low-income subsidy (LIS). Beneficiaries who normally get Extra Help / LIS cost-sharing reductions do not get them on Bridge claims. Everyone pays the same $50 — which, for the lowest-income beneficiaries, can actually be more than they’d pay for a normal covered drug.

Why $50 and not more? Behind the scenes, participating manufacturers provide the drugs to the program at a net price of $245 per monthly supply. The central processor pays the pharmacy the drug’s cost less your $50 copay, and the gap is absorbed within the demonstration’s economics rather than by your plan.

Prior Authorization: The Heart of the Program

Every Bridge fill requires prior authorization (PA) — but it works differently from a normal Part D PA, because it goes to the central processor, not your plan.

Who submits it, and when

• PA requests cannot be submitted or processed before July 1, 2026.
• The typical flow: your prescriber sends a prescription to a pharmacy; the pharmacy triggers a request for the prescriber to complete the prior authorization, usually delivered via electronic prior authorization (ePA) or fax within 24–72 hours.
• Prescribers submit the PA request and the prescription to the central processor — not to the beneficiary’s Part D plan.

What the prescriber must attest

The prescriber’s attestation is the core of the PA. They must confirm that:

• The beneficiary is prescribed the drug to reduce excess body weight and maintain weight reduction, in combination with ongoing lifestyle modification (structured nutrition and physical activity), consistent with the FDA-approved label; and
• The beneficiary is ≥ 18 years old and met the applicable BMI + condition criterion at the time GLP-1 therapy was initiated.

Critically, the clinician must attest that all BMI records and medical-history criteria are completely true and accurate — under penalty of perjury. This is an unusually strong standard for a drug PA, and it puts the documentation burden squarely on the prescriber. The clinician should have the BMI-at-initiation and qualifying-diagnosis records in the chart to back the attestation.

Renewals and switching

Here’s the patient-friendly part: once your first fill is approved, subsequent fills do not require a new prior authorization — as long as you stay on the same drug. If you switch from one covered GLP-1 to another (say, Wegovy to Zepbound KwikPen, or to Foundayo), a new prior authorization is required.

There is no step-therapy requirement built into the Bridge — you are not forced to fail a cheaper drug first. The gate is the clinical criteria and the attestation, not a mandated treatment sequence.

The Claims Process, End to End

This is the part pharmacists most need to understand, because the Bridge routes around the normal Part D plumbing.

Pharmacies

• Pharmacies do not need to opt in. Any pharmacy can process Bridge claims.
• Claims are submitted electronically using the NCPDP Telecommunication Standard to the central processor, routed on a dedicated BIN (028918) and PCN (MEDDGLP1BR) rather than the beneficiary’s normal Part D BIN/PCN. Paper claims and direct member reimbursements are not accepted.
• On the prescription side, CMS mapped the clinical criteria to ICD-10 codes but does not publish a single required-code list; in practice the prescriber includes an obesity diagnosis code from the E66 family plus the routing note “SEND TO BRIDGE FOR WEIGHT MANAGEMENT,” and the attestation — not a specific diagnosis code — is what establishes eligibility.
• At the counter, the pharmacy collects the $50 copay from the beneficiary, and the central processor pays the pharmacy.
• Reimbursement to the pharmacy is at the drug’s wholesale acquisition cost (WAC) less the beneficiary copay, plus a dispensing fee, plus applicable sales tax.
• The dispensing fee is $3 per claim — or $5 for a beneficiary residing in long-term care.

Part D plans and manufacturers

• Part D sponsors carry no risk for Bridge drugs and do not have to opt in. The drugs sit outside the plan’s benefit entirely.
• Manufacturers participate by furnishing the eligible drugs at the $245 net monthly price. Manufacturer participation is what makes a given drug available through the Bridge.

Step-by-step: what actually happens at the counter

1. Your prescriber writes a prescription for a covered GLP-1 for weight management and sends it to your pharmacy.
2. The pharmacy submits a claim to the central processor via NCPDP. Because it’s a first fill, the system flags that a prior authorization is needed.
3. The central processor sends a PA request to your prescriber (ePA or fax), typically within 24–72 hours.
4. Your prescriber completes the attestation (BMI-at-initiation, qualifying condition, weight-management use, lifestyle modification) and submits it to the central processor.
5. Once approved, the claim adjudicates. You pay $50, the pharmacy dispenses, and the central processor reimburses the pharmacy (WAC − $50 + dispensing fee + tax).
6. On refills of the same drug, no new PA is needed — you just pay your $50. Switch drugs and the PA cycle restarts.

Bridge vs. the BALANCE Model

People conflate these two, so it’s worth separating them:

• The Medicare GLP-1 Bridge is the temporary, CMS-run demonstration described in this article. It’s live now (July 1, 2026 – December 31, 2027), uses a central processor, and is the mechanism actually delivering $50 drugs today.
• The BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is the longer-term CMS Innovation Center model for GLP-1 coverage in Medicaid and, potentially later, Medicare Part D. Participation in BALANCE is voluntary for manufacturers, state Medicaid agencies, and Part D plans.

The Bridge’s data-collection role is meant to inform whether and how BALANCE eventually rolls into Part D. Think of the Bridge as the interim, and BALANCE as the (still-being-shaped) permanent framework.

What This Means for You

If you’re a Medicare beneficiary who’s been priced out of GLP-1s, the Bridge is genuinely transformative — $50/month for FDA-approved Wegovy, Zepbound KwikPen, or Foundayo is a fraction of the $1,000+ list prices these drugs once carried, and it’s competitive with (or cheaper than) most compounded options while carrying full manufacturer quality assurance.

But go in with clear eyes about the limitations:

• It’s temporary (through December 31, 2027). Have a conversation with your prescriber about what happens after — whether BALANCE, ordinary Part D, or another pathway will carry you forward.
• The $50 doesn’t count toward your out-of-pocket cap, so if you take other costly Part D drugs, budget accordingly.
• No LIS/Extra Help applies, so the lowest-income beneficiaries don’t get their usual discount here.
• The exclusions are strict — a single 2026 Part D GLP-1 fill, or a qualifying diagnosis like type 2 diabetes/OSA/MASH, routes you off the Bridge and into (or back to) regular Part D coverage.

How to get started

1. Confirm you’re enrolled in a PDP or MA-PD plan.
2. Check the clinical criteria and exclusions above against your own history.
3. Talk to a prescriber who can document your BMI at GLP-1 initiation and any qualifying condition, and who is prepared to complete the attestation.
4. Verify details at Medicare.gov/glp1bridge or 1-800-MEDICARE.

For help choosing a telehealth or manufacturer-direct provider that can handle the prescription and PA, see our updated Best GLP-1 Providers rankings and the July 2026 provider updates.

Sources

• CMS — Medicare GLP-1 Bridge and Information for Providers, Pharmacies, and Part D Plans
• CMS — Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications
• AMCP — CMS Releases Frequently Asked Questions on the Medicare GLP-1 Bridge
• KFF — What to Know About the BALANCE Model and the Medicare GLP-1 Bridge and Nearly Four Million Beneficiaries Met the Eligibility Criteria
• Medicare Rights Center — GLP-1 Weight-Loss Drug Demonstration Begins July 2026
• Eli Lilly — What Medicare Part D patients need to know about accessing Foundayo and Zepbound
• CBS News — Medicare to cover GLP-1 drugs for weight loss starting July 1

Last updated: July 3, 2026. Program rules are set by CMS and may change; verify specifics with your plan, pharmacy, prescriber, or 1-800-MEDICARE before making decisions. This article is educational and is not medical, legal, or financial advice.